Amgen vs Pfizer at a glance
Both companies operate in the Health Care sector, so these figures are broadly like-for-like.
| Metric | AMGN | PFE |
|---|---|---|
| Market cap | $235.24B | $159.34B |
| Price | $432.42 | $27.96 |
| P/E ratio (TTM) | 22.89 | 17.56 |
| P/B ratio (MRQ) | 20.38 | 1.58 |
| P/S ratio (TTM) | 4.8 | 2.18 |
| Revenue growth (1Y) | 9.92% | -1.65% |
| Return on equity (TTM) | 89.06% | 8.99% |
| Return on invested capital (TTM) | 14.50% | 10.60% |
| Gross margin (TTM) | 72.65% | 71.32% |
| Net margin (TTM) | 22.93% | 6.81% |
| Dividend yield (TTM) | 2.33% | 6.15% |
How they differ
Amgen is the larger company at $235.24B versus $159.34B — about 1.5x the size.
On trailing earnings, Pfizer is the cheaper of the two at 17.56 against 22.89 for Amgen.
On sales, Pfizer is the cheaper of the two at 2.18 against 4.8 for Amgen.
Amgen leads on revenue growth over the past year, 9.92% against -1.65%.
Amgen leads on return on invested capital, 14.50% against 10.60%.
Amgen leads on gross margin, 72.65% against 71.32%.
Pfizer offers the higher yield at 6.15% against 2.33%.
Go deeper
Ratios describe the past. Whether either is worth owning depends on what you pay today.
Related comparisons
Other matchups involving Amgen or Pfizer.